Conference Reports for NATAP

IAS 2019: Conference on HIV Pathogenesis Treatment and Prevention Mexico City July 21-24 2019 Back

Tolerability, Safety, and Efficacy of Islatravir (MK-8591) at Doses of 0.25 to 2.25 mg QD, in Combination With Doravirine and Lamivudine Through 24 Weeks in Treatment-Naïve AdultsWith HIV-1 Infection       Reported by Jules Levin 10th IAS Conference on HIV Science (IAS 2019), 21-24 July 2019, Mexico City, Mexico